ArticleEndocrine2025
Laser ablation for the treatment of nonfunctioning benign thyroid nodules: a single center, 10-year retrospective study.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Thermal Ablation as a Non-Surgical Alternative for Thyroid Nodules: A Review of Current Evidence.Medicina (Kaunas, Lithuania) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the outcomes of symptomatic nonfunctioning benign thyroid nodules treated with laser ablation (LA) over a 10-year follow-up.
methodsThis retrospective study included patients treated with LA between January 2010 and December 2014 and followed for 10 years. The patient's nodule volume was recorded at baseline, after 6 months, and then annually from the date of the LA procedure. We assessed the volume reduction ratio (VRR), technique efficacy, regrowth rate, additional treatments (surgery or LA), and complications.
resultsOne hundred nine patients were included in the study cohort. The 1-year VRR was 56.3%; technique efficacy was detected in 76 of 109 patients (69.7%). Sixty-nine out of 109 (63.3%) patients did not require a second treatment (LA or surgery) and these 69/109 (63.3%) patients showed a stable VRR of 65%. Regrowth was observed in 28 of 109 (25.7%) patients. EU-TIRADS 2 category, intranodular vascularity, and delivered energy ≥500 J/mL prevented technique inefficacy, regrowth, and retreatment (LA or surgery). Transient complications occurred in 3 out of 109 (2.7%) patients.
conclusionIn this 10-year follow-up study, benign thyroid nodules submitted to LA experienced a stable VRR of 65% in more than 60% of patients. To maximize VRR and technique efficacy, LA should be particularly used in EU-TIRADS 2 nodules with intranodular vascularity that should preferably receive ≥ 500 J/mL of energy.
Indexed as
Identifiers
40500583What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.